Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nazem Atassi

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Clinical and Translational Science|November 27, 2023
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participantsAgnes Hincelin-Mery, Xavier Nicolas, Cathy Cantalloube, et al.
Journal of Neurotrauma|June 19, 2019
Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain InjuryDustin W Wooten, Laura Ortiz-Terán, Nevena Zubcevik, et al.
Journal of the Peripheral Nervous System : JPNS|April 29, 2023
An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathyLuis Querol, Richard A Lewis, Hans-Peter Hartung, et al.
Molecular Imaging and Biology|October 7, 2017
PET Imaging of Human Brown Adipose Tissue with the TSPO Tracer [<sup>11</sup>C]PBR28Chongzhao Ran, Daniel S Albrecht, Miriam A Bredella, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurology and Therapy|November 28, 2025
Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World StudyHans-Peter Hartung, Nazem Atassi, Miguel Alonso-Alonso, et al.
Cytotherapy|October 11, 2016
Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?Nazem Atassi, Ettore Beghi, Miguel Blanquer, et al.
Drug Discovery Today|September 11, 2014
Neuroprotective agents target molecular mechanisms of disease in ALSYongjin Zhu, Anastasios Fotinos, Lilly L J Mao, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
Neurology|September 6, 2013
Analysis of start-up, retention, and adherence in ALS clinical trialsNazem Atassi, Padmaja Yerramilli-Rao, Jackie Szymonifka, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Clinical and Translational Science|November 27, 2023
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participantsAgnes Hincelin-Mery, Xavier Nicolas, Cathy Cantalloube, et al.
Journal of Neurotrauma|June 19, 2019
Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain InjuryDustin W Wooten, Laura Ortiz-Terán, Nevena Zubcevik, et al.
Journal of the Peripheral Nervous System : JPNS|April 29, 2023
An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathyLuis Querol, Richard A Lewis, Hans-Peter Hartung, et al.
Molecular Imaging and Biology|October 7, 2017
PET Imaging of Human Brown Adipose Tissue with the TSPO Tracer [<sup>11</sup>C]PBR28Chongzhao Ran, Daniel S Albrecht, Miriam A Bredella, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurology and Therapy|November 28, 2025
Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World StudyHans-Peter Hartung, Nazem Atassi, Miguel Alonso-Alonso, et al.
Cytotherapy|October 11, 2016
Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?Nazem Atassi, Ettore Beghi, Miguel Blanquer, et al.
Drug Discovery Today|September 11, 2014
Neuroprotective agents target molecular mechanisms of disease in ALSYongjin Zhu, Anastasios Fotinos, Lilly L J Mao, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
Neurology|September 6, 2013
Analysis of start-up, retention, and adherence in ALS clinical trialsNazem Atassi, Padmaja Yerramilli-Rao, Jackie Szymonifka, et al.
Pageof 8